These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16908170)

  • 1. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.
    Sallem W; Serradji N; Dereuddre-Bosquet N; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):7999-8013. PubMed ID: 16908170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
    J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives.
    Wang T; Kadow JF; Zhang Z; Yin Z; Gao Q; Wu D; Parker DD; Yang Z; Zadjura L; Robinson BA; Gong YF; Spicer TP; Blair WS; Shi PY; Yamanaka G; Lin PF; Meanwell NA
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5140-5. PubMed ID: 19664921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601].
    Martin M; Serradji N; Dereuddre-Bosquet N; Bensaïd O; Fichet G; Lamouri A; Heymans F; Clayette P; Godfroid JJ; Dormont D
    Pathol Biol (Paris); 2000 Jun; 48(5):513-9. PubMed ID: 10949851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies.
    Zhan P; Liu X; Li Z; Fang Z; Li Z; Wang D; Pannecouque C; Clercq ED
    Bioorg Med Chem; 2009 Aug; 17(16):5920-7. PubMed ID: 19620009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterobiaryl human immunodeficiency virus entry inhibitors.
    Lu RJ; Tucker JA; Pickens J; Ma YA; Zinevitch T; Kirichenko O; Konoplev V; Kuznetsova S; Sviridov S; Brahmachary E; Khasanov A; Mikel C; Yang Y; Liu C; Wang J; Freel S; Fisher S; Sullivan A; Zhou J; Stanfield-Oakley S; Baker B; Sailstad J; Greenberg M; Bolognesi D; Bray B; Koszalka B; Jeffs P; Jeffries C; Chucholowski A; Sexton C
    J Med Chem; 2009 Jul; 52(14):4481-7. PubMed ID: 19534463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of N-methylpiperazine for the preparation of piperazine-based unsymmetrical bis-ureas as anti-HIV agents.
    El-Faham A; Armand-Ugón M; Esté JA; Albericio F
    ChemMedChem; 2008 Jul; 3(7):1034-7. PubMed ID: 18383064
    [No Abstract]   [Full Text] [Related]  

  • 11. Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.
    Lu RJ; Tucker JA; Zinevitch T; Kirichenko O; Konoplev V; Kuznetsova S; Sviridov S; Pickens J; Tandel S; Brahmachary E; Yang Y; Wang J; Freel S; Fisher S; Sullivan A; Zhou J; Stanfield-Oakley S; Greenberg M; Bolognesi D; Bray B; Koszalka B; Jeffs P; Khasanov A; Ma YA; Jeffries C; Liu C; Proskurina T; Zhu T; Chucholowski A; Li R; Sexton C
    J Med Chem; 2007 Dec; 50(26):6535-44. PubMed ID: 18052117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP
    Pharmazie; 1997 Sep; 52(9):672-5. PubMed ID: 9411454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains.
    Moret V; Dereudre-Bosquet N; Clayette P; Laras Y; Pietrancosta N; Rolland A; Weck C; Marc S; Kraus JL
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5988-92. PubMed ID: 17000109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
    J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells.
    Takahashi T; Nishizawa Y; Hato F; Shintaku H; Maeda N; Fujiwara N; Inaba M; Kobayashi K; Kitagawa S
    Microvasc Res; 2007 Jan; 73(1):29-34. PubMed ID: 17027041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors.
    Xu B; Sun Y; Guo Y; Cao Y; Yu T
    Bioorg Med Chem; 2009 Apr; 17(7):2767-74. PubMed ID: 19269831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
    Chen S; Chen R; He M; Pang R; Tan Z; Yang M
    Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity.
    Vermeire K; Lisco A; Grivel JC; Scarbrough E; Dey K; Duffy N; Margolis L; Bell TW; Schols D
    Biochem Pharmacol; 2007 Aug; 74(4):566-78. PubMed ID: 17603023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.